Regeneron’s total addressable commercial market is expected to exceed $220 billion by 2030. Some near-term highlights include: ...

Amalthea Fund highlighted stocks like Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the Q3 2024 investor letter. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biopharmaceutical company ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of $1,186.00. Discover outperforming stocks and invest smarter ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of the National Institutes of Health’s All of Us million-person program ...

Regeneron collaborates with Truveta and leading American health systems to massively extend its DNA-linked healthcare database to further advance scientific innovation and healthcare delivery ...

DNA sequencing company Illumina and biotech Regeneron have invested in electronic health record data company Truveta to create the largest and most diverse database of genetic information in the ...